MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Epizyme Operating Income 2011-2025 | EPZM
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -238 M | -225 M | -177 M | -128 M | -137 M | -112 M | -133 M | -55 M | -3.13 M | -768 K | -21 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -768 K | -238 M | -112 M |
Quarterly Operating Income Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -29.8 M | -50.9 M | - | -64.1 M | -58.2 M | -64.3 M | -62.1 M | -54.4 M | -57.6 M | -51.4 M | -57.5 M | -38 M | -50.7 M | -31 M | -24.3 M | -38.6 M | -30.3 M | -35 M | -37.4 M | -38.1 M | -28.5 M | -33 M | -35.5 M | -24.8 M | -28.4 M | -23.1 M | -22.3 M | -23.1 M | -25.8 M | -61.4 M | -15.1 M | -19.7 M | -13.3 M | -6.91 M | 16.3 M | -9.73 M | -2.18 M | -7.48 M | -4.54 M | 4.44 M | 4.8 M | -5.48 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.3 M | -64.3 M | -30.2 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 25.37 | -2.07 % | $ 1.23 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-78.1 M | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-142 M | $ 3.28 | -2.53 % | $ 254 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 210.49 | 0.16 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 9.56 | 0.75 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.35 | 3.07 % | $ 14.8 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 89.88 | -0.46 % | $ 96.9 B | Britain |
 |
Baudax Bio
BXRX
|
-56.8 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
ChromaDex Corporation
CDXC
|
7.73 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 568.3 | -2.19 % | $ 43 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-22.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
-226 M | - | -7.23 % | $ 13 M | USA |
 |
Biogen
BIIB
|
7.04 B | $ 174.78 | 1.32 % | $ 25.4 B | USA |
 |
BioVie
BIVI
|
-18.1 M | $ 1.46 | -3.31 % | $ 2.16 M | USA |
 |
Cortexyme
CRTX
|
-34.6 M | - | -1.05 % | $ 67.1 M | USA |
 |
Benitec Biopharma
BNTC
|
-9.83 M | $ 12.34 | -4.78 % | $ 508 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-211 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 11.5 | 0.52 % | $ 744 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 94.85 | -1.2 % | $ 27.2 B |  Germany |
 |
Eloxx Pharmaceuticals
ELOX
|
-34.4 M | - | -5.68 % | $ 8.28 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 0.28 | -2.28 % | $ 609 M | Israel |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 14.62 | -4.54 % | $ 962 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Cerus Corporation
CERS
|
-14.2 M | $ 2.17 | 0.7 % | $ 401 M | USA |
 |
Enochian Biosciences
ENOB
|
-189 M | - | - | $ 40.5 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.15 | 0.16 % | $ 1.5 B | Britain |